Tag Archives: humira biosimilar

fifth arthritis biosimilar

FDA Approves A Fifth Biosimilar for Arthritis, But Three Are Still Not Available

The number of biosimilars approved by the Food and Drug Administration (FDA) continues to grow in the United States, and they are slowly becoming available to consumers.

In late August, the FDA approved Cyltezo (adalimumab-adbm), a second biosimilar to Humira (adalimumab). But like the first biosimilar, Amjevita (adalimumab-atto), which was approved in September 2016, it is not yet available to U.S. consumers because of pending patent litigation with AbbVie, the manufacturer of Humira.

Continue reading FDA Approves A Fifth Biosimilar for Arthritis, But Three Are Still Not Available

Arthritis Biosimilar

FDA Approves Third Biosimilar for Arthritis – Amjevita, a Biosimilar to Humira

The U.S. Food and Drug Administration (FDA) on Friday approved the third biosimilar to treat inflammatory types of arthritis – but, like the two that were previously approved, this one will not be available to patients until patent disputes are resolved.
Continue reading FDA Approves Third Biosimilar for Arthritis – Amjevita, a Biosimilar to Humira